MannKind (MNKD) Shares Gap Up to $2.11

MannKind Co. (NASDAQ:MNKD) gapped up prior to trading on Thursday . The stock had previously closed at $2.06, but opened at $2.11. MannKind shares last traded at $2.24, with a volume of 5466583 shares changing hands.

Several equities research analysts have recently weighed in on the company. BidaskClub upgraded MannKind from a “hold” rating to a “buy” rating in a research note on Thursday. Leerink Swann assumed coverage on MannKind in a research note on Monday, March 4th. They issued an “outperform” rating and a $3.00 price objective on the stock. Svb Leerink assumed coverage on MannKind in a research note on Monday, March 4th. They issued an “outperform” rating and a $3.00 price objective on the stock. Finally, ValuEngine upgraded MannKind from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $3.06.

The firm has a market capitalization of $391.55 million, a P/E ratio of -3.80 and a beta of 2.68.



MannKind (NASDAQ:MNKD) last announced its earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.22 by ($0.28). During the same period last year, the business earned ($0.28) earnings per share. Sell-side analysts forecast that MannKind Co. will post -0.32 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the company. CAPROCK Group Inc. acquired a new position in shares of MannKind in the 4th quarter worth approximately $42,000. Virtu Financial LLC acquired a new position in shares of MannKind in the 4th quarter worth approximately $50,000. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of MannKind by 196.1% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 55,407 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 36,694 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of MannKind by 82.3% in the 2nd quarter. Bank of America Corp DE now owns 123,414 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 55,721 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in MannKind by 300.5% during the 3rd quarter. Alliancebernstein L.P. now owns 154,600 shares of the biopharmaceutical company’s stock worth $283,000 after buying an additional 116,000 shares in the last quarter. 33.37% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “MannKind (MNKD) Shares Gap Up to $2.11” was posted by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://dakotafinancialnews.com/2019/03/15/mannkind-mnkd-shares-gap-up-to-2-11.html.

About MannKind (NASDAQ:MNKD)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States.

Read More: Book Value Of Equity Per Share – BVPS Explained

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.